SCHEMBL3002010

SCHEMBL3002010

CCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
SMN1; SMN2 Q16637 7/20 0.53
MAPK1 P28482 5/20 0.53
LMNA P02545 4/20 0.53
NPSR1 Q6W5P4 2/20 0.52
TSHR P16473 1/20 0.52
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
ALDH1A1 P00352 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 2/20 0.44
HSD17B10 Q99714 1/20 0.44
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
FFAR2 O15552 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017814 0.92 MAPT (0.52) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3016149 0.92 SMN1; SMN2 (0.48) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3006940 0.92 SMN1; SMN2 (0.58) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3003095 0.91 SMN1; SMN2 (0.55) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3008283 0.90 SMN1; SMN2 (0.50) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3011619 0.90 SMN1; SMN2 (0.54) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3014390 0.90 SMN1; SMN2 (0.58) MAPTSMN1; SMN2MAPK1LMNATSHR
SCHEMBL3002006 0.90 KMT2A (0.47) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3015877 0.89 AR (0.47) MAPTSMN1; SMN2MAPK1LMNANPSR1
SCHEMBL3011327 0.89 SMN1; SMN2 (0.48) MAPTSMN1; SMN2MAPK1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.